0307 GMT - Sigma Healthcare's elevated profile from its impending merger with Chemist Warehouse and its likely inclusion as one of Australia's 100 largest listed companies earn the pharmaceutical supplier a new bull at Morgans. Analyst Scott Power raises his recommendation on the stock to add from hold, telling investors that Sigma will attract significant passive buying from funds if, as he expects, it is included in Australia's S&P/ASX 100 and other global indexes. He adds a 30% liquidity premium to his valuation as a result. Target price rises 35% to A$2.98. Shares are up 0.4% at A$2.68. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 16, 2024 22:07 ET (03:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。